Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?
- PMID: 33798462
- PMCID: PMC8009615
- DOI: 10.1016/S2213-8587(21)00059-0
Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?
Conflict of interest statement
I have received personal fees for lectures and advisory board memberships from Boehringer Ingelheim, Eli Lilly, Mundipharma, AstraZeneca, and Takeda.
Comment on
-
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.Lancet Diabetes Endocrinol. 2021 May;9(5):293-303. doi: 10.1016/S2213-8587(21)00050-4. Epub 2021 Mar 30. Lancet Diabetes Endocrinol. 2021. PMID: 33798464 Free PMC article.
References
-
- Khunti K, Knighton P, Zaccardi F, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 2021 doi: 10.1016/S2213-8587(21)00050-4. published online March 30. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
